Startup profile · funding coverage
Sensible Biotechnologies funding, valuation and investors
Biotechnology company designing and manufacturing naturally modified mRNA inside engineered living cells.
Keep track of Sensible Biotechnologies
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A equity plus non-dilutive funding
$47M package, including up to $20M non-dilutive · October 6, 2026
Latest known valuation
Undisclosed
Series A equity plus non-dilutive funding · October 6, 2026
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Oxford, United Kingdom and Bratislava, Slovakia
Investors in latest funding
Lead: Oxford Science Enterprises
Other: OTB Ventures , In-Q-Tel , Recode Ventures , Isomer Capital , Y Combinator
Overview
Sensible Biotechnologies develops an integrated cell-based platform for mRNA design, optimization and manufacturing.
Why Sensible Biotechnologies is interesting
Its biological manufacturing approach could change the purity, cost and performance profile of mRNA, but still needs reproducible scale and regulatory validation.
Product & use cases
Sensible uses engineered cells, high-throughput screening and computational design to produce and optimize naturally modified mRNA molecules.
- mRNA therapeutic design
- Cell-based mRNA manufacturing
- High-throughput sequence screening
Key facts
- Announced a $47M package combining Series A equity with up to $20M in non-dilutive funding.
- The company did not separately disclose the Series A amount; Axios reported $27M.
Funding history (newest first)
Series A equity plus non-dilutive funding
2026-10-06 $47M package, including up to $20M non-dilutive Valuation: Undisclosed- Oxford Science Enterprises (lead)
- OTB Ventures (participant)
- In-Q-Tel (participant)
- Recode Ventures (participant)
- Isomer Capital (participant)
- Y Combinator (participant)
Source: https://www.sensible.bio/
Investors in our directory
Funds linked from Sensible Biotechnologies's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Integrated sequence design and cell-based production rather than relying exclusively on conventional cell-free synthesis.
Competes with established enzymatic mRNA production and emerging synthetic-biology platforms for RNA manufacturing.
-
CureVac incumbent
mRNA design and therapeutic development.
-
GreenLight Biosciences adjacent
RNA manufacturing and biological production.
-
Conventional IVT manufacturing alternative
Established cell-free mRNA production process.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Sensible Biotechnologies's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.